Digital twins, virtual models of patients created from clinical data, are set to transform clinical trials by improving efficiency and addressing challenges like costs and patient recruitment. Technologies such as causal generative AI enhance these models, allowing for simulations of treatment outcomes. The digital twin market in clinical trials was valued at $1.17 billion in 2022 and is projected to reach $38.43 billion by 2032, attracting interest from major pharmaceutical companies and regulatory agencies.